Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI - Scorecard - MDSpire
Advertisement
Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI
Clinical Scorecard: Concurrent Assessment of Cerebral Blood Flow, Vascular Permeability, and Leakage in Gliomas via Dynamic Spin-and-Gradient-Echo Echoplanar Imaging MRI
At a Glance
Category
Detail
Condition
Brain gliomas with heterogeneous prognosis influenced by vascular and molecular features
Key Mechanisms
Neoangiogenesis causing dysfunctional neovasculature and blood–brain barrier breakdown; contrast agent leakage quantified by MRI techniques
Target Population
Adult patients with diffuse gliomas (astrocytoma, oligodendroglioma, glioblastoma), both newly diagnosed and recurrent
Dynamic SAGE-EPI MRI enables simultaneous acquisition of perfusion, permeability, and leakage maps using a single contrast agent dose.
Dual-echo DSC separates T1 and T2* contributions, allowing computation of novel biomarkers like TRATE, independent of acquisition parameters.
TRATE correlates with cytoarchitectural features and may differentiate aggressive gliomas (IDH wild-type, high Ki67) from less aggressive types.
Guideline-Based Recommendations
Diagnosis
Use dynamic SAGE-EPI MRI to non-invasively quantify vascular density (rCBV), BBB permeability (Ktrans), and leakage effects in gliomas.
Employ dual-echo DSC sequences to disentangle T1 and T2* leakage effects for improved tumor characterization.
Integrate perfusion and permeability imaging into clinical brain tumor protocols to aid grading, molecular profiling, and differential diagnosis.
Management
Administer a single dose of Gadavist® (Gadobutrol) contrast agent (~0.1 mL/kg) during dynamic SAGE-EPI acquisition to reduce gadolinium exposure.
Leverage simultaneous perfusion and permeability data to distinguish treatment effects from tumor recurrence.
Monitoring & Follow-up
Monitor changes in TRATE and ΔR1,ss metrics as potential indicators of tumor aggressiveness and response to therapy.
Use quantitative MRI biomarkers to track BBB permeability and vascular changes longitudinally.
Risks
Be cautious of gadolinium deposition risks and adverse effects in patients with impaired renal function; minimize contrast dose by using combined imaging sequences.
Patient & Prescribing Data
Adult patients with enhancing diffuse gliomas undergoing surgical resection
Single-dose Gadavist® contrast administration during dynamic SAGE-EPI MRI provides comprehensive vascular and permeability assessment without additional scanning time or contrast load.
Clinical Best Practices
Adopt dynamic SAGE-EPI MRI protocols to obtain dual-echo DSC data for simultaneous perfusion and permeability imaging.
Process dual-echo data to separate T1 and T2* effects, enabling calculation of PSR, TRATE, and ΔR1,ss biomarkers.
Correlate imaging biomarkers with histopathological markers such as Ki67 and IDH mutation status for comprehensive tumor evaluation.
Standardize acquisition parameters to ensure reproducibility and comparability of leakage effect metrics across institutions.
by Francesco Sanvito, Catalina Raymond, Nicholas S. Cho, Jingwen Yao, Akifumi Hagiwara, Joey Orpilla, Linda M. Liau, Richard G. Everson, Phioanh L. Nghiemphu, Albert Lai, Robert Prins, Noriko Salamon, Timothy F. Cloughesy, Benjamin M. Ellingson
